Mirae Asset Global Investments Co. Ltd. Increases Stock Position in Healthpeak Properties, Inc. (NYSE:PEAK)

Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Healthpeak Properties, Inc. (NYSE:PEAK – Get Rating) by 17.7% during the fourth quarter, HoldingsChannel.com reports. The fund owned 104,611 shares of the company’s stock after buying an additional 15,750 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Healthpeak Properties were worth $2,623,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in the stock. Iron Horse Wealth Management LLC boosted its holdings in shares of Healthpeak Properties by 300.0% in the fourth quarter. Iron Horse Wealth Management LLC now owns 1,000 shares of the company’s stock worth $25,000 after buying an additional 750 shares during the last quarter. Newbridge Financial Services Group Inc. purchased a new position in shares of Healthpeak Properties in the fourth quarter worth approximately $25,000. CENTRAL TRUST Co boosted its holdings in shares of Healthpeak Properties by 321.3% in the third quarter. CENTRAL TRUST Co now owns 1,226 shares of the company’s stock worth $28,000 after buying an additional 935 shares during the last quarter. EverSource Wealth Advisors LLC boosted its holdings in shares of Healthpeak Properties by 270.8% in the third quarter. EverSource Wealth Advisors LLC now owns 1,294 shares of the company’s stock worth $30,000 after buying an additional 945 shares during the last quarter. Finally, Certified Advisory Corp purchased a new position in shares of Healthpeak Properties in the first quarter worth approximately $33,000. Hedge funds and other institutional investors own 92.04% of the company’s stock.

Healthpeak Properties Trading Down 1.8 %

Healthpeak Properties stock opened at $19.28 on Friday. The stock has a market cap of $10.55 billion, a P/E ratio of 19.09, a PEG ratio of 2.34 and a beta of 0.89. The company has a debt-to-equity ratio of 0.90, a current ratio of 0.61 and a quick ratio of 0.61. Healthpeak Properties, Inc. has a 1 year low of $19.18 and a 1 year high of $30.10. The firm’s 50 day moving average price is $21.04 and its 200-day moving average price is $23.92.

Healthpeak Properties Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, May 19th. Stockholders of record on Monday, May 8th were given a dividend of $0.30 per share. This represents a $1.20 annualized dividend and a dividend yield of 6.22%. The ex-dividend date of this dividend was Friday, May 5th. Healthpeak Properties’s payout ratio is currently 118.81%.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. Citigroup downgraded shares of Healthpeak Properties from a “buy” rating to a “neutral” rating and set a $23.00 price objective on the stock. in a report on Wednesday, April 5th. Morgan Stanley raised their price objective on shares of Healthpeak Properties from $23.00 to $25.00 and gave the stock an “equal weight” rating in a report on Friday, March 10th. Mizuho upgraded shares of Healthpeak Properties from a “neutral” rating to a “buy” rating and decreased their target price for the stock from $29.00 to $25.00 in a research note on Monday, April 24th. Stifel Nicolaus decreased their target price on shares of Healthpeak Properties from $34.00 to $30.00 in a research note on Friday, April 28th. Finally, Wells Fargo & Company started coverage on shares of Healthpeak Properties in a research note on Wednesday, April 19th. They set an “equal weight” rating and a $23.00 target price on the stock. Six investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $27.42.

Insider Activity

In other Healthpeak Properties news, CEO Scott M. Brinker purchased 16,300 shares of Healthpeak Properties stock in a transaction that occurred on Thursday, March 2nd. The shares were bought at an average price of $23.63 per share, for a total transaction of $385,169.00. Following the completion of the transaction, the chief executive officer now owns 206,525 shares of the company’s stock, valued at approximately $4,880,185.75. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Healthpeak Properties news, Director Sara Grootwassink Lewis purchased 4,000 shares of Healthpeak Properties stock in a transaction that occurred on Wednesday, March 15th. The shares were bought at an average price of $21.43 per share, for a total transaction of $85,720.00. Following the completion of the transaction, the director now owns 4,000 shares of the company’s stock, valued at approximately $85,720. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Scott M. Brinker purchased 16,300 shares of Healthpeak Properties stock in a transaction that occurred on Thursday, March 2nd. The stock was acquired at an average price of $23.63 per share, for a total transaction of $385,169.00. Following the transaction, the chief executive officer now directly owns 206,525 shares of the company’s stock, valued at approximately $4,880,185.75. The disclosure for this purchase can be found here. Insiders have purchased a total of 21,817 shares of company stock worth $506,099 over the last quarter. Insiders own 0.19% of the company’s stock.

Healthpeak Properties Profile

(Get Rating)

Healthpeak Properties, Inc is a real estate investment trust, which engages in the acquisition, development, ownership, and management of healthcare real estate. It operates through the following business segments: Life Science, Medical Office and Continuing Care Retirement Community (CCRC). The Life Science segment contains laboratory and office space primarily for biotechnology, medical device and pharmaceutical companies, scientific research institutions, government agencies, and other organizations involved in the life science industry.